ES2548299A1 - Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama - Google Patents

Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama Download PDF

Info

Publication number
ES2548299A1
ES2548299A1 ES201430349A ES201430349A ES2548299A1 ES 2548299 A1 ES2548299 A1 ES 2548299A1 ES 201430349 A ES201430349 A ES 201430349A ES 201430349 A ES201430349 A ES 201430349A ES 2548299 A1 ES2548299 A1 ES 2548299A1
Authority
ES
Spain
Prior art keywords
risk
mir
seq
present
translation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201430349A
Other languages
English (en)
Other versions
ES2548299B2 (es
Inventor
José LOZANO CASTRO
Emilio ALBA CONEJO
Luís Gustavo PÉREZ RIVAS
José JEREZ ARAGONÉS
Nuria RIBELLES ENTRENA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Malaga
Servicio Andaluz de Salud
Instituto Mediterraneo para el Avance de la Biotecnologia y la Investigacion Sanitaria (Fundacion Imabis)
Original Assignee
Universidad de Malaga
Servicio Andaluz de Salud
Instituto Mediterraneo para el Avance de la Biotecnologia y la Investigacion Sanitaria (Fundacion Imabis)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Malaga, Servicio Andaluz de Salud, Instituto Mediterraneo para el Avance de la Biotecnologia y la Investigacion Sanitaria (Fundacion Imabis) filed Critical Universidad de Malaga
Priority to ES201430349A priority Critical patent/ES2548299B2/es
Priority to EP15760852.2A priority patent/EP3144395B1/en
Priority to US15/125,714 priority patent/US10059998B2/en
Priority to PCT/ES2015/070179 priority patent/WO2015136141A1/es
Publication of ES2548299A1 publication Critical patent/ES2548299A1/es
Application granted granted Critical
Publication of ES2548299B2 publication Critical patent/ES2548299B2/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se sitúa en el campo de la oncología y el tratamiento del cáncer. La presente invención incluye métodos para pronosticar el riesgo de recurrencia de tumores de mama empleando la firma de expresión de determinados miARNs. Específicamente, la presente invención se refiere a un procedimiento para determinar el riesgo de recurrencia de cáncer de mama que comprende medir los niveles de expresión de al menos un miARN seleccionado de entre el grupo que consiste en miR-149-5p (SEQ ID NO: 1), miR-10a-5p, (SEQ ID NO: 2), miR-20b-5p, (SEQ ID NO: 3), miR-30a-3p (SEQ ID NO: 4); y miR-342-5p, (SEQ ID NO: 5) en una muestra del tumor, en el que una alteración del nivel de expresión de al menos un miARN en el tumor, con respecto al nivel de expresión en una muestra control, es indicativa de un elevado riesgo de recurrencia del tumor. Además, la presente invención se refiere a herramientas y kits para llevar a cabo el procedimiento de la presente invención.
ES201430349A 2014-03-13 2014-03-13 Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama Expired - Fee Related ES2548299B2 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES201430349A ES2548299B2 (es) 2014-03-13 2014-03-13 Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama
EP15760852.2A EP3144395B1 (en) 2014-03-13 2015-03-13 Microrna signature as an indicator of the risk of early recurrence in patients with breast cancer
US15/125,714 US10059998B2 (en) 2014-03-13 2015-03-13 Microrna signature as an indicator of the risk of early recurrence in patients with breast cancer
PCT/ES2015/070179 WO2015136141A1 (es) 2014-03-13 2015-03-13 Firma de microarn como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430349A ES2548299B2 (es) 2014-03-13 2014-03-13 Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama

Publications (2)

Publication Number Publication Date
ES2548299A1 true ES2548299A1 (es) 2015-10-15
ES2548299B2 ES2548299B2 (es) 2016-05-13

Family

ID=54070984

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201430349A Expired - Fee Related ES2548299B2 (es) 2014-03-13 2014-03-13 Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama

Country Status (4)

Country Link
US (1) US10059998B2 (es)
EP (1) EP3144395B1 (es)
ES (1) ES2548299B2 (es)
WO (1) WO2015136141A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102601499B1 (ko) * 2015-11-06 2023-11-13 연세대학교 산학협력단 miRNA 발현 수준으로부터 UQCRB 관련 질병을 진단하는 방법
WO2019177550A1 (en) 2018-03-10 2019-09-19 Koc Universitesi Therapeutic nanoparticles containing argonaute for microrna delivery and compositions and methods using same
AR128976A1 (es) 2022-03-11 2024-07-03 Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Diagnóstico y tratamiento de cáncer de mama

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE447040T1 (de) * 2002-09-03 2009-11-15 Quanta Biosciences Inc Verbesserte zusammensetzungen und verfahren für die cdna-synthese
CA2780222C (en) * 2009-11-04 2021-11-16 Diamir, Llc Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
US20130065778A1 (en) 2010-01-26 2013-03-14 Yale University MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy
EP2545190A1 (en) * 2010-03-11 2013-01-16 National University of Ireland Galway Detection and quantification of micrornas in the circulation and the use of circulating micrornas as biomarkers for cancer
CA2800557A1 (en) * 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
WO2013057567A1 (en) 2011-10-19 2013-04-25 Council Of Scientific And Industrial Research (C.S.I.R.) Biomarkers useful for detection of types, grades and stages of human breast cancer
WO2013110053A1 (en) 2012-01-20 2013-07-25 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
EP2682477A1 (en) 2012-07-06 2014-01-08 National University of Ireland, Galway miR-181a and miR652 as oncologic biomarker of breast cancer

Also Published As

Publication number Publication date
US10059998B2 (en) 2018-08-28
EP3144395A4 (en) 2018-01-03
US20170002424A1 (en) 2017-01-05
EP3144395A1 (en) 2017-03-22
EP3144395B1 (en) 2019-11-20
WO2015136141A1 (es) 2015-09-17
ES2548299B2 (es) 2016-05-13

Similar Documents

Publication Publication Date Title
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
EP3744859A3 (en) Microrna biomarker for the diagnosis of gastric cancer
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
CY1122233T1 (el) Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
MX341840B (es) Biomarcadores de microarn indicativos de la enfermedad de alzheimer.
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
NZ629538A (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
IN2012DN04944A (es)
MX2017003387A (es) Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogenetica de cancer colorrectal metastasico.
MX2017009998A (es) Biomarcadores para cancer pancreatico.
MX2017002654A (es) Deteccion temprana de cancer de pulmon por clasificacion fenotipica por metilacion de adn de celulas derivadas de esputo.
WO2018097614A3 (ko) 유방암 환자의 화학치료 유용성 예측 방법
MX2018005867A (es) Integracion de las caracteristicas tumorales con el indice de cancer de mama.
EP3444362A3 (en) Circulating mirnas as early detection marker and prognostic marker
ES2548299A1 (es) Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
MX2017003832A (es) Metodo para la prediccion de sensibilidad a un tratamiento con un inhibidor de egfr.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2548299

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20160513

FD2A Announcement of lapse in spain

Effective date: 20230726